尼妥珠单抗联合吉西他滨加顺铂方案治疗晚期胰腺癌临床疗效观察  

Primary study of nimotuzumab combined with gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

作　　者：秦苑[1] 任东 范宇飞 刘晓林 李定纲[1] 

机构地区：[1]北京市海淀医院肿瘤血液科,北京100080 [2]北京市燕化医院肿瘤科,北京102500

出　　处：《实用临床医药杂志》2011年第9期64-66,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察尼妥珠单抗(nimotuzumab)联合吉西他滨(gemcitabine,GEM)加顺铂(cisplatin,CDDP)(GP)方案治疗晚期胰腺癌(APC)的近期疗效及不良反应。方法 2007年5月～2010年8月,共有16例住院的APC患者采用尼妥珠单抗联合GP方案治疗,具体方案如下:尼妥珠单抗200 mg,每周1次,连用8周,此后同样剂量每2周静脉输注,直至疾病进展;化疗方案采用GEM 800～1 000 mg/m2,按固定剂量率法(FDR)静脉输注,第1、8天,CDDP 30 mg/m2静脉注射,第2～4天,每21天重复1次。结果 16例患者中部分缓解(PR)8例,稳定(SD)5例,和进展(PD)3例。有效率50%,疾病控制率81%。常见的不良反应为恶心、呕吐,白细胞及血小板减少,未见Ⅳ级不良反应。结论妥珠单抗联合GP方案治疗APC安全有效,值得进一步扩大样本研究。Objective To evaluate the efficacy and side effects of gemcitabine（GEM） and cisplatin（CDDP） chemotherapy combined with nimotuzumab in advanced pancreatic cancer（APC）.Methods From May 2007 to Aug.2010,sixteen cases of APC were included in this study.Patients were given nimotuzumab 200 mg IV weekly for 8 weeks,and then continued receiving nimotuzumab treatment every two weeks until disease progression or unacceptable toxicity occurred.The chemotherapy was as below： GEM 800～1000 mg/m2 FDR IV,d1 and d8,CDDP 30 mg/m2 IV,d2～d4.It was repeated every 21 days.Results Grade Ⅰ～Ⅱ of nausea,vomiting,skin rash and bone marrow suppression were found.Grade Ⅲ of thrombopenia was found in one case.There were 8 cases with PR,5 cases with SD,3 cases with PD.Conclusion Nimotuzumab combined with GEM and CDDP regimen was effective and well tolerated in patients with advanced pancreatic cancer.It deserves enlargement of samples and further investigation.

关 键 词：胰腺癌 尼妥珠单抗 联合化疗 靶向治疗 表皮生长因子受体单抗 

分 类 号：R735.9[医药卫生—肿瘤]